Inhibition of proteolytic processing of adenoviral proteins by ε-aminocaproic acid and ambenum in adenovirus-infected cells

• Authors: Lidiya Nosach , Nataliya Dyachenko , Valentina Zhovnovataya , Miron Lozinskiy , Victor Lozitsky
• Languages of publication: EN

Abstracts

EN

Maturation of adenovirus particles is markedly affected by proteolytic processing. The possibility for blocking the conversion of precursor structural core protein (preVII) into mature structure protein VII by officinal drugs ε-aminocaproic acid and ambenum has been demonstrated in Hep-2 cells infected with adenovirus. Proteolytic processing may be regarded as one of the targets for inhibiting adenovirus reproduction.

Keywords

EN

adenoviral proteins; ε-aminocaproic acid; adenovirus; ambenum

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 4
• Pages: 1005-1012

Dates

published

2002

revised

2002-09-19

received

2002-11-19

accepted

2002-12-04

Contributors

author

Lidiya Nosach

• Institute of Microbiology and Virology NAS of Ukraine, Kyiv, Ukraine

author

Nataliya Dyachenko

• Institute of Microbiology and Virology NAS of Ukraine, Kyiv, Ukraine

author

Valentina Zhovnovataya

• Institute of Microbiology and Virology NAS of Ukraine, Kyiv, Ukraine

author

Miron Lozinskiy

• Institute of Organic Chemistry NAS of Ukraine, Kyiv, Ukraine

author

Victor Lozitsky

• Ukrainian Research Anti-Plague Institute, Odessa, Ukraine

References

• Alexeeva I, Palchikovskaya L, Shalamay A, Nosach L, Zhovnovataya V, Povnitsa O, Dyachenko N. (2000) N-4-Amino-acid derivatives of 6-azacytidine:structure-activity relationship. Acta Biochim Polon.; 47: 95-101.
• Anderson CW. (1990) The proteinase polypeptide of adenovirus serotype 2 virions. Virology.; 177: 259-72.
• Anderson CW, Baum S, Gesteland RF. (1973) The processing of adenovirus 2-induced proteins. J Virol.; 12: 241-52.
• Bhatti A, Weber J. (1979) Protease of adenovirus type 2: partial characterization. Virology.; 96: 478-85.
• Cotten M, Weber JM. (1995) The adenovirus protease is required for virus entry to host cells. Virology.; 213: 494-502.
• De Clercq E. (1997) In search of a selective antiviral chemotherapy. Clin Microbiol Rev.; 10: 674-95.
• De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res.; 8: 261-72.
• Durham PJ, Johnson RH. (1984) Plaque titration and inhibition test for bovine parvovirus. J Gen Virol.; 65: 1425-9.
• Dyachenko N, Rybalko S, Nosach L, Alexeeva I, Shalamay A. (1999) Antiadenovirus and antiherpes virus activity of 6-azacytidine. Antiviral Res.; 41: 60.
• Gordon YJ, Araullo-Cruz TP, Johnson YP, Romanowski EG, Kinchington PR. (1996a) Isolation of human adenovirus type 5 variants resistant to the antiviral Cidofovir. Invest Ophthalmol Vis Sci.; 37: 2774-8.
• Gordon YJ, Nalsenz L, De Clercq E, Mangel P, Veckencear M. (1996b) Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea.; 15: 546.
• Gordon YJ, Romanowski E, Azaullo-Cruz T, Seaberg L, Erzurum S, Tolman R, De Clercq E. (1991) Inhibitory effect of ( S)-HPMPC, ( S)-HPMPA and 2 nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res.; 16: 11-6.
• Greber UF, Webster P, Weber JM, Helenius A. (1996) The role of the adenovirus protease on virus entry into cells. EMBO J.; 15: 1766-77.
• Hillenkamp J, Reinhard T, Ross RS, Bohringer D, Cartshurg O, Roggendorf M, De Clercq E, Godehardt E, Sudmacher R. (2002) The effect of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology.; 109: 845-50.
• Horwitz MS. (1985) Adenoviral diseases. In Virology. Fields DN ed, pp 477-95, Raven Press, New York.
• Horwitz MS. (2001) Adenovirus immunoregulatory genes and their cellular targets. Virology.; 279: 1-8.
• Hu JM, Hsiung GD. (1989) Evaluation of new antiviral agents. I. In vitro perspectives. Antiviral Res.; 11: 217-32.
• Landau SM, Nosach LN, Pavlova GV. (1982) Morphological method for estimation of simian virus 40 infections titer. Arch Virol.; 73: 79-84.
• Lozitsky VP, Fedtchouk AS, Girlya Yu. (1994) Antiviral activity of proteolytic inhibitor ambenum ( para-aminomethylbenzoic acid). Antiviral Res.; 23: 172.
• Mentel R, Kinder M, Wegner U, Janta-Lipinski M, Matthes E. (1997) Inhibitory activity of 3-fluoro-2-deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antiviral Res.; 34: 113-9.
• Mentel R, Kurek S, Wegner U, Janta-Lipinski M, Gurtler L, Matthes E. (2000) Inhibition of adenovirus DNA polymerase by modified nucleoside triphosphate analogs correlate with their antiviral effects on cellular level. Med Microbiol Immunol.; 189, 91-5.
• Munoz FM, Piedra PA, Demmler GJ. (1998) Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis.; 27: 1194-200.
• Nosach LN, Butenko SI, Timofeeva MYa, Dyachenko NS, Tikhomirova TP, Alexeeva IV, Chernetsky VP. (1989) Analysis of DNA synthesized in the adenovirus-infected cells under the effect of nucleoside analogs. Mikrobiol Zh.; 51:73-5. (in Ukrainian).
• Nosach LN, Dyachenko NS, Butenko SI, Zhovnovataya VL, Shevchenko LI. Lozinsky MA. (1994) The effect of some drugs on proteolytic processing of adenoviral proteins. Antiviral Res.; 23, 160.
• Nosach L, Dyachenko N, Zovnovataya V, Butenko S, Chernomas A, Shipulina L. (2000) Influence of Hyporamin on a reproduction of adenovirus in cell culture. Liki.; 3-4: 57-60 (in Ukrainian)
• Romanowski EG, Yates KA, Gordon YJ. (2001) Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zeland rabbit ocular model. Antiviral Res.; 52: 275-80.
• Ruzindana-Umunyana A, Sircar S, Weber JM. (2000) The effect of mutant peptide cofactors on adenovirus protease activity and virus infection. Virology.; 270: 173-9.
• Sircar S, Keyvani-Amineh H, Weber JM. (1996) Inhibition of adenovirus infection with protease inhibitors. Antiviral Res.; 30: 147-53.
• Sircar S, Ruzindana-Umunyana A, Neugebauer W, Weber JM. (1998) Adenovirus endopeptidase and papain are inhibited by the some agents. Antiviral Res.; 40: 45-51.
• Thanyi K, Bourbonniere M, Houde A, Rancourd C, Weber J. (1993) Isolation and properties of the adenovirus type 2 proteinase. J Biol Chem.; 268: 1780-5.
• Weber J. (1972) Titration of adenovirus by counting cells containing virus-induced inclusions bodies. Appl Microbiol.; 23: 1025-6.
• Weber J. (1976) Genetic analysis of adenovirus type 2. III Temperature sensitivity of processing of viral proteins. J Virol.; 17: 462-71.
• Weber J. (1995) Adenovirus endopeptidase and its role in virus assembly. Curr Top Microbiol Immunol.; 199: 227-35.
• Webster A, Russel WC, Kemp GD. (1989) Characterization of the adenovirus proteinase: development and use of a specific peptide assay. J Gen Virol.; 70, 3215-23.
• Zarubaev VV, Suchinin VP, Dyachenko NS, Nosach LN. (2000) Effect of 6-azacytidine on experimental adenoviral infection. Antiviral Res.; 46: 106.